文献速递头颈与中枢神经肿瘤

Debio 1143联合大剂量顺铂化放疗治疗高危局部晚期头颈部鳞癌:双盲多中心随机2期研究

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
PubMed 文献 · Lancet Oncol · 2020-08-03

两组3级及以上不良事件发生率相似(85% vs 87%),但Debio 1143组吞咽困难和黏膜炎更常见。

要点

  • Debio 1143组3级及以上不良事件发生率85%,与安慰剂组87%相当,但吞咽困难和黏膜炎更常见。
  • 该研究为首个在高危局部晚期头颈鳞癌中较大剂量顺铂化放疗对照显示优效的随机试验,需3期研究确认。

核心结论

  • 抑制凋亡蛋白抑制剂(IAP)是此预后不良人群中有前景的新策略,需3期研究确认。

研究设计与样本

  • 双盲、多中心、随机、2期研究,由法国头颈放疗肿瘤学组(GORTEC)在法国和瑞士19家医院开展。
  • 主要终点为化放疗后18个月局部区域控制率,在意向治疗人群分析,并在符合方案人群重复。

主要发现

  • 18个月局部区域控制率:Debio 1143组26/48(54%;95%CI 39-69),安慰剂组16/48(33%;95%CI 20-48)。
  • 3级及以上不良事件:Debio 1143组41/48(85%),安慰剂组41/47(87%)。
  • 最常见3-4级不良事件:吞咽困难(Debio 1143组24例[50%] vs 安慰剂组10例[21%])、黏膜炎(15例[31%] vs 10例[21%])、贫血(17例[35%] vs 11例[23%])。
  • 严重治疗中出现的不良事件:Debio 1143组30/48(63%),安慰剂组28/47(60%)。
  • 安慰剂组2例(4%)因不良事件死亡(多器官衰竭和窒息,均与治疗无关),Debio 1143组无因不良事件死亡。

关键数值与推荐

  • Debio 1143用法:口服200 mg/日,21天周期中第1-14天给药,共3周期。
  • 安慰剂用法:口服20 mg/mL,给药计划同Debio 1143。

临床怎么用

  • 对于高危局部晚期头颈鳞癌,Debio 1143联合大剂量顺铂化放疗可能提高局部区域控制,但需3期研究确认后方可改变临床实践。
  • 治疗期间需关注吞咽困难、黏膜炎和贫血等不良反应,尤其Debio 1143组吞咽困难和黏膜炎发生率更高。

局限性

  • 研究仅纳入高危、重度吸烟且无远处转移的局部晚期头颈鳞癌患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Debio 1143 is an orally available antagonist of inhibitor of apoptosis proteins with the potential to enhance the antitumour activity of cisplatin and radiotherapy. The radiosensitising effect of Debio 1143 is mediated through caspase activation and TNF, IFNγ, CD8 T cell-dependent pathways. We aimed to investigate the efficacy and safety of Debio 1143 in combination with standard chemoradiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. METHODS: This double-blind, multicentre, randomised, phase 2 study by the French Head and Neck Radiotherapy Oncology Group (GORTEC) was run at 19 hospitals in France and Switzerland. Eligible patients were aged 18-75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0-3, and M0] disease), Eastern Cooperative Oncology Group performance status of 0 or 1, a history of heavy tobacco smoking (>10 pack-years) with no previous or current treatment for invasive head and neck cancer, and no previous treatment with inhibitor of apoptosis protein antagonists. Patients were randomly assigned (1:1) to receive oral Debio 1143 (200 mg per day on days 1-14 of 21-day cycles, for three cycles) or oral placebo (20 mg/mL, administered at the same dosing schedule) using a stochastic minimisation technique according to node involvement and primary tumour site, and HPV-16 status in patients with an oropharyngeal primary tumour site. All patients received standard high-dose cisplatin chemoradiotherapy. The primary endpoint was the proportion of patients with locoregional control 18 months after chemoradiotherapy, analysed in the intention-to-treat population (primary analysis), and repeated in the per-protocol population. Responses were assessed according to Response Evaluation Criteria in Solid Tumors (version 1.1). This trial is registered with ClinicalTrials.gov, NCT02022098, and is still active but not recruiting. FINDINGS: Between Jan 25, 2016, and April 24, 2017, 48 patients were randomly assigned to the Debio 1143 group and 48 to the placebo group (one patient in the placebo group did not receive the study drug and was not included in the safety analysis). Median duration of follow-up was 25·0 months (IQR 19·6-29·4) in the Debio 1143 group and 24·2 months (6·6-26·8) in the placebo group. Locoregional control 18 months after chemoradiotherapy was achieved in 26 (54%; 95% CI 39-69) of 48 patients in the Debio 1143 group versus 16 (33%; 20-48) of 48 patients in the placebo group (odds ratio 2·69 [95% CI 1·13-6·42], p=0·026). Grade 3 or worse adverse events were reported in 41 (85%) of 48 patients in the Debio 1143 group and in 41 (87%) of 47 patients in the placebo group. The most common grade 3-4 adverse events were dysphagia (in 24 [50%] patients in the Debio 1143 group vs ten [21%] in the placebo group), mucositis (in 15 [31%] vs ten [21%]), and anaemia (in 17 [35%] vs 11 [23%]). Serious treatment-emergent adverse events were recorded in 30 (63%) of 48 patients in the Debio 1143 group and 28 (60%) of 47 in the placebo group. In the placebo group, two (4%) deaths were due to adverse events (one multiple organ failure and one asphyxia; neither was considered to be related to treatment). No deaths due to adverse events occurred in the Debio 1143 group. INTERPRETATION: To our knowledge, this is the first treatment regimen to achieve superior efficacy in this disease setting against a high-dose cisplatin chemoradiotherapy comparator in a randomised trial. These findings suggest that inhibition of inhibitor of apoptosis proteins is a novel and promising approach in this poor prognostic population and warrant confirmation in a phase 3 study with the aim of expanding the therapeutic options for these patients. FUNDING: Debiopharm.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Sun XS, Tao Y, Le Tourneau C, et al. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncol. 2020. PMID: 32758455. doi:10.1016/S1470-2045(20)30327-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。